<DOC>
	<DOCNO>NCT02333760</DOCNO>
	<brief_summary>An open follow study patient enrol Phase 1/2 clinical trial haematopoietic stem cell gene therapy Wiskott-Aldrich Syndrome treat autologous CD34+ cell transduce w1.6_hWASP_WPRE ( VSVg ) lentiviral vector .</brief_summary>
	<brief_title>Gene Therapy WAS Follow-up</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<criteria>Patients enrol initial phase I/II WAS conduct France United Kingdom ( GTG002.07 GTG003.08 ) . Parents , guardian patient sign informed consent , guardians patient sign informed consent â€¢ Parents , guardian , patient unwilling return follow study period .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>